George Matcham
Direttore/Membro del Consiglio presso INSTIL BIO, INC.
Patrimonio netto: 419 269 $ in data 31/05/2024
Posizioni attive di George Matcham
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| INSTIL BIO, INC. | Direttore/Membro del Consiglio | 01/09/2018 | - |
| Independent Dir/Board Member | 01/09/2018 | - |
Storia della carriera di George Matcham
Precedenti posizioni note di George Matcham
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| CHIMERIC THERAPEUTICS LIMITED | Direttore/Membro del Consiglio | 05/07/2021 | 03/08/2023 |
| CELGENE | Corporate Officer/Principal | 01/05/2013 | 01/06/2018 |
Celgene Cellular Therapeutics
 Celgene Cellular Therapeutics Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Celgene Cellular Therapeutics develops human pharmaceuticals. The company is based in Warren, NJ. The company was founded by Robert Joseph Hariri Gordon. | Direttore operativo | - | - |
Formazione di George Matcham
| University of Cardiff | Doctorate Degree |
| University of Cambridge | Graduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 4 |
| Regno Unito | 3 |
| 2 |
Posizioni
| Director/Board Member | 2 |
| Independent Dir/Board Member | 1 |
| Chief Operating Officer | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| INSTIL BIO, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Celgene Cellular Therapeutics
Celgene Cellular Therapeutics Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Celgene Cellular Therapeutics develops human pharmaceuticals. The company is based in Warren, NJ. The company was founded by Robert Joseph Hariri Gordon. | Health Technology |
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
| Chimeric Therapeutics Ltd. (Australia) |
- Borsa valori
- Insiders
- George Matcham
- Esperienza
